Cytokinetics

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cytokinetics focuses on aficamten development post-FDA action, eyes international growth

Cytokinetics is navigating challenges post-CRL for omecamtiv mecarbil while focusing on aficamten's development.
Financially, the company is balancing increased expenses with revenue growth and strategic investments in R&D.
Key milestones for 2023 include FDA meetings for omecamtiv mecarbil and data expectations for aficamten.
The company's emphasis on aficamten's differentiation and clinical progress signals a strategic shift in focus.

Cytokinetics shifts focus to cardiovascular pipeline, optimistic outlook ahead

Cytokinetics focusing on cardiovascular pipeline progress, redirecting resources.
Optimistic outlook for aficamten and other cardiovascular drug candidates.
Financially stable with cash reserves and strategic cost-saving measures.

Cytokinetics reports strong Q2 progress, eyes market expansion opportunities

Cytokinetics made significant strides in Q2 2023, advancing key studies and reducing operating spending to enhance financial stability.
Positive data and progress in cardiovascular therapies showcase the company's potential in treating HCM and positioning in the market.
While facing challenges in stock performance and data disclosures, Cytokinetics remains poised for growth with opportunities in novel therapies and market expansion.

Cytokinetics excels in Q3 with aficamten progress and commercial readiness

Cytokinetics demonstrated strong operational and financial performance in Q3 2023, with a focus on advancing the aficamten program and preparing for potential commercialization.
While facing challenges related to data interpretation complexities and real-world beta blocker usage, the company remains well-positioned with compelling clinical aspects of aficamten.
Opportunities lie in potential partnerships for capital access, broad market potential across regions, and upcoming data disclosures driving market differentiation.

Cytokinetics excels with positive aficamten trial results and strategic focus

Cytokinetics' Q4 2023 marked a significant milestone with positive aficamten trial results, strong financial standing, and strategic focus on regulatory advancements and market expansion.
The company's strengths lie in aficamten's efficacy, financial stability, and potential for differentiated labeling, while challenges include adoption transitions and data analysis complexities.
Opportunities abound in accelerating NDA submission, expanding patient reach, engaging with payors, and leveraging data insights for enhanced patient outcomes and market positioning.
Overall, Cytokinetics is poised for growth and impact in 2024, with a clear roadmap for success in advancing aficamten and maximizing its therapeutic potential in the HCM market.

Cytokinetics advances aficamten for HCM treatment amid financial strength

Cytokinetics is making significant strides in advancing aficamten for HCM treatment, supported by positive results and regulatory engagements.
The company's financial strength and strategic focus on commercial readiness position it well for future growth and market penetration.
Challenges lie in addressing unmet needs in pediatric HCM, enrollment completion for ongoing trials, and establishing treatment credibility.
Opportunities exist in expanding diagnosis potential, developing competitive treatment options, and enhancing regulatory alignment for global market access.

Cytokinetics advances obstructive HCM treatment with strong financials and strategic focus

Cytokinetics is poised for growth with FDA submission for aficamten and strong financial position.
Strategic focus on commercial preparations and clinical trials signals a commitment to future success.
Challenges in market competition and education require targeted efforts for successful product launch.
Emphasis on patient-centric approach and category expansion positions the company for market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cytokinetics, Incorporated (NASDAQ:CYTK ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications & Investor Relations Robert Blum - President & Chief Executive Officer Fady Malik - Executive Vice President, Research & Development Stuart Kupfer - Vice President & Chief Medical Officer Andrew Callos - EVP & Chief Commercial Officer Robert Wong - Vice President & Chief Accounting Officer Ching Jaw - Senior Vice President & Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Dane Leone - Raymond James Salim Syed - Mizuho Serge Belanger - Needham Jason Butler - JMP Securities Srikripa Devarakonda - Truist Securities Yasmeen Rahimi - Piper Sandler Charles Duncan - Cantor Roanna Ruiz - Leerink Partners Justin Kim - Oppenheimer & Co. Operator Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Third Quarter 2023 Conference Call.

Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript

Cytokinetics (CYTK) came out with a quarterly loss of $1.35 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.28 per share a year ago.

Cytokinetics (CYTK) Reports Q3 Loss, Misses Revenue Estimates

On Track for Topline Results from SEQUOIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Obstructive HCM, in Late December

Cytokinetics Reports Third Quarter 2023 Financial Results

The mean of analysts' price targets for Cytokinetics (CYTK) points to a 75.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Cytokinetics (CYTK) Could Rally 75.5%: Here's is How to Trade

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in November:

Cytokinetics to Participate in Upcoming Investor Conferences

Heart diseases-focused drug developer Cytokinetics is weighing options after receiving takeover interest, Bloomberg News reported on Tuesday, citing people familiar with the matter.

Cytokinetics exploring options after receiving takeover interest - Bloomberg News

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 2, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.

Cytokinetics to Announce Third Quarter Results on November 2, 2023

New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten, Show Sustained Improvements in Clinical Efficacy Endpoints and No Treatment Interruptions for Low Ejection Fraction

Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

Cytokinetics (CYTK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Cytokinetics (CYTK) Soars 11.4%: Is Further Upside Left in the Stock?

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the baseline characteristics of patients randomized in SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of A ficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were presented at the HCM Society Scientific Sessions in Cleveland, Ohio by Martin S.

Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a virtual Investor and Analyst Day on Thursday, October 19, 2023 from 8:30 AM to 11:30 AM ET. The event, entitled New Horizons in Hypercontractility, will feature presentations from senior leaders about the Company's cardiac myosin inhibition programs in hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), including new longer-term data from FOREST-HCM (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open-label extension clinical study of aficamten in patients with HCM, pre-clinical data for CK-4021586 (CK-586), a novel cardiac myosin inhibitor being developed for the potential treatment of patients with HFpEF, and an update on Cytokinetics' commercial readiness activities and corporate strategy.

Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023

Baseline Characteristics from SEQUOIA-HCM to be Presented at HCMS Scientific Sessions on October 6, 2023 Baseline Characteristics from SEQUOIA-HCM to be Presented at HCMS Scientific Sessions on October 6, 2023

Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases

Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program

AGCO

Alaska Air Group

Banking on the Goldilocks narrative, targeting the best mid-cap stocks centers mostly on balance. If you go the small-capitalization route, you'll benefit from maximum upside potential.

The 3 Best Mid-Cap Stocks to Buy Now: September 2023

Expanding Development Program to Assess Potential of Aficamten in Additional Patient Population to Inform Increased Utility of Cardiac Myosin Inhibition Expanding Development Program to Assess Potential of Aficamten in Additional Patient Population to Inform Increased Utility of Cardiac Myosin Inhibition

Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated (NASDAQ:CYTK ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications & Investor Relations Robert Blum - President & Chief Executive Officer Fady Malik - Executive Vice President, Research & Development Steve Heitner - VP:Clinical Research & Therapeutic Area Lead at Cytokinetics Inc. Andrew Callos - Executive Vice President & Chief Commercial Officer Robert Wong - Vice President & Chief Accounting Officer Ching Jaw - Senior Vice President & Chief Financial Officer Conference Call Participants Jason Butler - JMP Jason Zemansky - BofA. Joe Pantginis - H.C.

Cytokinetics, Incorporated (CYTK) Q2 2023 Earnings Call Transcript

Cytokinetics (CYTK) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of $0.23 per share a year ago.

Cytokinetics (CYTK) Reports Q2 Loss, Misses Revenue Estimates

Completed Enrollment in SEQUOIA-HCM,  Pivotal Phase 3 Trial of Aficamten in Obstructive HCM;  On Track for Topline Results by the End of the Year

Cytokinetics Reports Second Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 31, 2023 it granted stock options to purchase an aggregate of 60,200 shares of common stock to 3 new employees, whose employment commenced in July 2023, as a material inducement to their employment.

Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 3, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.

Cytokinetics to Announce Second Quarter Results on August 3, 2023

Cytokinetics, a biopharmaceutical company specializing in muscle dysfunction therapies, has seen a significant increase in earnings, driven by its commitment to research and development. The company's financial growth is also attributed to its unique drug mechanisms, strategic management, and investment in personnel and pre-commercial launch efforts. Cytokinetics has several products under development, including treatments for hypertrophic cardiomyopathy and heart failure, which set it apart in the competitive biopharmaceutical landscape.

Aficamten Sets Cytokinetics Apart In Cardiomyopathy

First Phase 3 Trial Evaluating Monotherapy with a Cardiac Myosin Inhibitor Compared to Monotherapy with a Beta Blocker in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I

Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress

SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one Late Breaking Clinical Trial presentation and two moderated ePoster presentations at Heart Failure 2023 an International Congress of the European Society of Cardiology taking place online and in Prague, Czech Republic from May 20, 2023 – May 23, 2023.

Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress

Advancement of Additional Cardiac Myosin Inhibitor Expands Specialty Cardiovascular Portfolio Advancement of Additional Cardiac Myosin Inhibitor Expands Specialty Cardiovascular Portfolio

News for Cytokinetics Stock (CYTK)